Navigation Links
Sequenom Enters Into New $30.0 Million Credit Facility
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine® (Sequenom CMM) have secured a $30.0 million financing commitment from Silicon Valley Bank’s San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.

The credit facility consists of a term loan of up to $20.0 million, and a $10.0 million revolving line of credit to be used for the purchase of capital equipment to expand laboratory capacity and to fund working capital requirements, accounts receivable and inventory as Sequenom CMM prepares to commercialize and launch new laboratory developed tests.  

"The addition of this new credit facility enables us to extend the runway provided by financings put in place over the last year and to maintain a consistent level of liquidity as we move into an active growth phase for the company," said Paul V. Maier, CFO of Sequenom, Inc.  

The Sequenom CMM laboratory in San Diego, Calif. was recently awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP), while the laboratory based in Grand Rapids, Mich. received its third re-accreditation based on the results of recent onsite inspections.  In May of 2011, laboratory director Daniel H. Farkas, Ph.D., H.C.L.D. was advised of this national recognition and congratulated for the excellence of the services being provided, making the laboratory one of more than 7,000 CAP-accredited facilities worldwide.  

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company commi
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
2. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
3. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
4. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
5. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
6. Sequenom to Present at Two Financial Conferences in September
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom Appoints Two New Board Members
9. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
10. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
11. SEQUENOM Announces Launch of MassARRAY Compact 96 System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Trial Programs Funded Through 2009, SAN FRANCISCO, ... Ottawa, Ontario), a clinical stage biopharmaceutical company,developing a ... announced the closing of a financing transaction with,gross ... of $8 million USD.,The offering was completed without ...
... or dusts be protected by UL certified lights that have an ... of these lights available for oil rig workers and paint spray ... ... 2008 -- OSHA requirements mandate that workers exposed to flammable vapors ...
... FRANCISCO, Sept. 9 VIA Pharmaceuticals,Inc. (Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... on Tuesday, September 16, 2008 at 12:00pm,Eastern Time ... Libby, Chief of,Cardiovascular Medicine at the Brigham and ...
Cached Biology Technology:Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 2Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 3Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 3VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 4
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... WASHINGTON, Pa., Nov. 30, 2011 ADFLOW Health ... digital messaging focused on Consumer Health Engagement and ... screening kiosks—Personal Health Centers™—in all Rite Aid locations. ... The agreement with ADFLOW demonstrates Rite ...
... WASHINGTON, Nov. 30Ultra-tiny zinc oxide (ZnO) particles with ... the ingredients list of some commercially available sunscreen products, ... beneath the outer layer of skin. To help ... from Australia and Switzerland have developed a way to ...
... a pair of physicians at Boston University School of Medicine ... development of a test that can help diagnose membranous nephropathy ... offered in the research setting and is awaiting commercial development, ... the disease. Currently, the only way to diagnose the disease ...
Cached Biology News:ADFLOW Health Networks to Provide Blood Pressure Screening Centers at Rite Aid Pharmacies Nationwide 2Scientists use laser imaging to assess safety of zinc oxide nanoparticles in sunscreen 2BUSM researchers develop blood test to detect membranous nephropathy 2
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: